Does the BMEZ insider report show any share transactions for Charles Park?

The insider data reports no share transactions for Charles Park, with zero buys, zero sells and no derivative exercises. It also shows no holding entries, indicating no securities positions are listed for him in this statement.

BlackRock Health Sciences Term Trust (BMEZ) reappoints compliance chief in 2026

Q: Who is identified as Chief Compliance Officer for BMEZ?

Charles Park is identified as Chief Compliance Officer of BlackRock Health Sciences Term Trust. He previously served in this role from January 28, 2020 to June 30, 2023 and has been reappointed effective August 1, 2026.

Q: What prior service period did Charles Park have at BMEZ?

Charles Park previously served as Chief Compliance Officer of BlackRock Health Sciences Term Trust from January 28, 2020 to June 30, 2023. The disclosure notes this earlier tenure before his reappointment effective August 1, 2026.

Q: When is Charles Park’s reappointment at BMEZ effective?

Charles Park’s reappointment as Chief Compliance Officer of BlackRock Health Sciences Term Trust is effective August 1, 2026. The statement also highlights his earlier service from January 28, 2020 to June 30, 2023.

Q: What role does Charles Park hold at BlackRock Health Sciences Term Trust (BMEZ)?

Charles Park holds the role of Chief Compliance Officer at BlackRock Health Sciences Term Trust. He served from January 28, 2020 to June 30, 2023 and has been reappointed effective August 1, 2026 according to the insider disclosure.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

BlackRock Health Sciences Term Trust reports that Charles Park is serving as its Chief Compliance Officer. Park previously held this role from January 28, 2020 to June 30, 2023 and has been reappointed effective August 1, 2026. No securities holdings or transactions are reported in this insider statement.

Key Figures

Prior CCO service start: January 28, 2020 Prior CCO service end: June 30, 2023 Reappointment effective date: August 1, 2026 +2 more

5 metrics

Prior CCO service start January 28, 2020 Start of Charles Park’s earlier Chief Compliance Officer tenure

Prior CCO service end June 30, 2023 End of Charles Park’s earlier Chief Compliance Officer tenure

Reappointment effective date August 1, 2026 Effective date of Charles Park’s reappointment as Chief Compliance Officer

Reported buy transactions 0 shares transactionSummary shows zero buyShares and buyCount

Reported sell transactions 0 shares transactionSummary shows zero sellShares and sellCount

Key Terms

Chief Compliance Officer, Reporting Person, Issuer

3 terms

Chief Compliance Officer regulatory

"The Reporting Person previously served as Chief Compliance Officer of the Issuer"

The chief compliance officer is the senior executive responsible for making sure a company follows laws, industry rules and its own internal policies, acting like a safety inspector for legal and ethical risks. Investors care because effective compliance reduces the chance of fines, lawsuits, operational disruption and reputational damage, so the officer’s competence and independence can materially affect future profits and risk exposure.

Reporting Person regulatory

"The Reporting Person previously served as Chief Compliance Officer of the Issuer"

Issuer regulatory

"served as Chief Compliance Officer of the Issuer from January 28, 2020"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Understanding Insider Trading Forms →

Available on EDGAR 08/05/2026 - 03:30 PM Accepted by SEC EDGAR 08/05/2026 - 03:30 PM

FAQ

Who is identified as Chief Compliance Officer for BMEZ?

Charles Park is identified as Chief Compliance Officer of BlackRock Health Sciences Term Trust. He previously served in this role from January 28, 2020 to June 30, 2023 and has been reappointed effective August 1, 2026.

What prior service period did Charles Park have at BMEZ?

Charles Park previously served as Chief Compliance Officer of BlackRock Health Sciences Term Trust from January 28, 2020 to June 30, 2023. The disclosure notes this earlier tenure before his reappointment effective August 1, 2026.

When is Charles Park’s reappointment at BMEZ effective?

Charles Park’s reappointment as Chief Compliance Officer of BlackRock Health Sciences Term Trust is effective August 1, 2026. The statement also highlights his earlier service from January 28, 2020 to June 30, 2023.

What role does Charles Park hold at BlackRock Health Sciences Term Trust (BMEZ)?

Charles Park holds the role of Chief Compliance Officer at BlackRock Health Sciences Term Trust. He served from January 28, 2020 to June 30, 2023 and has been reappointed effective August 1, 2026 according to the insider disclosure.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Park Charles

(Last)

(First)

(Middle)

50 HUDSON YARDS

(Street)

NEW YORK

10001

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
08/01/2026

3. Issuer Name and Ticker or Trading Symbol
BlackRock Health Sciences Term Trust [ BMEZ ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Compliance Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)

Explanation of Responses:

Remarks:

The Reporting Person previously served as Chief Compliance Officer of the Issuer from January 28, 2020 to June 30, 2023. The Reporting Person was reappointed as Chief Compliance Officer of the Issuer effective August 1, 2026.

No securities are beneficially owned.

	/s/ Gladys Chang as Attorney-in-Fact	08/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

Source: View Original Filing on SEC EDGAR